May 7, 2026
Analysis
Angelini Pharma's $4.1 Billion Acquisition of Catalyst Pharmaceuticals: A Strategic Move
Angelini Pharma's $4.1 billion acquisition of Catalyst Pharmaceuticals strengthens its position in brain health, signaling significant M&A trends.
Earnings
ESAB Corporation's Q1 2026 Financial Results: A Closer Look
ESAB Corporation reports Q1 2026 results, revealing key insights into industrial equipment demand and market positioning.
Markets
Critical Metals Corp Gains Approval for Strategic Rare Earth Acquisition in Greenland
Analysis
Apollo Funds' Strategic Acquisition of Prosol Group: Insights for Investors
Apollo Funds' acquisition of Prosol Group signals a significant shift towards defensive investments in the food sector.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
